Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. Fornaro L, et al. Among authors: zaniboni a. Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Ann Oncol. 2013. PMID: 23666916 Free article. Clinical Trial.
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Cremolini C, et al. Among authors: zaniboni a. Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23. Ann Oncol. 2015. PMID: 25712456 Free article. Clinical Trial.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators. Lonardi S, et al. Among authors: zaniboni a. Ann Oncol. 2016 Nov;27(11):2074-2081. doi: 10.1093/annonc/mdw404. Epub 2016 Aug 29. Ann Oncol. 2016. PMID: 27573560 Free article. Clinical Trial.
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, Santini D. Dell'Aquila E, et al. Among authors: zaniboni a. Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004. Ann Oncol. 2018. PMID: 29324972 Free article. Clinical Trial.
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A. Cremolini C, et al. Among authors: zaniboni a. Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20. Ann Oncol. 2018. PMID: 29873679 Free article.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Petrelli F, Rulli E, Labianca R, Lonardi S, Rosati G, Dotti K, Ronzoni M, Pella N, Pusceddu V, Banzi M, Zampino MG, Yasmina M, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Sobrero A; TOSCA Investigators. Petrelli F, et al. Among authors: zaniboni a. Ann Oncol. 2021 Jan;32(1):66-76. doi: 10.1016/j.annonc.2020.10.477. Epub 2020 Oct 21. Ann Oncol. 2021. PMID: 33098997 Free article. Clinical Trial.
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Rossini D, Boccaccino A, Sbrana A, Daniel F, Borelli B, Raimondi A, Santini D, Conca V, Tomasello G, Caponnetto S, Marmorino F, Zaniboni A, Buonadonna A, Masi G, Lonardi S, Pietrantonio F, Falcone A, Antonuzzo A, Cremolini C. Rossini D, et al. Among authors: zaniboni a. ESMO Open. 2021 Dec;6(6):100293. doi: 10.1016/j.esmoop.2021.100293. Epub 2021 Oct 22. ESMO Open. 2021. PMID: 34689001 Free PMC article.
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A; Italian Group for the Study of Gastrointestinal Cancer—GISCAD (see appendix for the list of coauthors). Labianca R, et al. Among authors: zaniboni a. Ann Oncol. 2011 May;22(5):1236-1242. doi: 10.1093/annonc/mdq580. Epub 2010 Nov 15. Ann Oncol. 2011. PMID: 21078826 Free article. Clinical Trial.
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S. Scartozzi M, et al. Among authors: zaniboni a. Ann Oncol. 2012 Jul;23(7):1706-12. doi: 10.1093/annonc/mdr558. Epub 2011 Nov 23. Ann Oncol. 2012. PMID: 22112971 Free article.
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. Pietrantonio F, et al. Among authors: zaniboni a. Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090. Ann Oncol. 2018. PMID: 29538669 Free article.
364 results